CORRECTION Open Access

Correction to: miR-18a reactivates the Epstein-Barr virus through defective DNA damage response and promotes genomic instability in EBV-associated lymphomas



Pengfei Cao^{1,2†}, Meili Zhang^{1,2,5†}, Lujuan Wang^{1,2,3}, Buqing Sai^{1,2,3}, Jiuqi Tang², Zhaohui Luo², Cijun Shuai⁴, Liyang Zhang⁵, Zheng Li^{1,2,3}, Yanjin Wang⁶, Guiyuan Li^{1,2,3} and Juanjuan Xiang^{1,2,3*}

Following publication of the original article [1], the authors reported that they had supplied the incorrect figure for publication.

Cao et al. BMC Cancer (2018) 18:1293. https://doi.org/10.1186/s12885-018-5205-9

Following publication of the original article [1], the authors reported that they had supplied the incorrect figure for publication. The correct figure is displayed below. The authors apologise for the error.

Author details

¹Key Laboratory of Carcinogenesis of Ministry of Health, Xiangya Hospital, Central South University, Changsha 410078, Hunan, China. ²Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of EducationCancer Research Institute, Central South University, Changsha 410078, Hunan, China. ³Hunan Key Laboratory of Nonresolving inflammation and Cancer, Desease Genome Research Center, The Third Xiangya Hospital, Central South University, Changsha 410013, Hunan, China. ⁴State Key Laboratory of High Performance Complex Manufacturing, Central South University, Changsha 410083, Hunan, China. ⁵People's Hospital of Dezhou, Dezhou 253045, Shandong, China. ⁶Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha 410078, Hunan, China.

Received: 18 February 2019 Accepted: 19 February 2019 Published online: 01 March 2019

Reference

 Cao et al. BMC Cancer (2018) .miR-18a reactivates the Epstein-Barr virus through defective DNA damage response and promotes genomic instability in EBV-associated lymphomas. BMC Cancer 18:1293. https://doi.org/10.1186/ s12885-018-5205-9

Full list of author information is available at the end of the article



^{*} Correspondence: xiangjj@csu.edu.cn

[†]Pengfei Cao and Meili Zhang contributed equally to this work.

¹Key Laboratory of Carcinogenesis of Ministry of Health, Xiangya Hospital, Central South University, Changsha 410078, Hunan, China

²Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of EducationCancer Research Institute, Central South University, Changsha 410078, Hunan, China

Cao et al. BMC Cancer (2019) 19:189 Page 2 of 2




Fig. 2 miR-18a promotes cell proliferation in EBV-positive lymphoma cells. **a** miR-18a promoted tumor cell growth in vitro in EBV-positive lymphoma cell lines. CCK-8 cell viability assay was performed after the transfection of miR-18a mimics or miR-18a inhibitor into EBV-positive lymphoma cell lines (P3HR-1, Raji, EBV infected BJAB) and the EBV-negative lymphoma cell line BJAB. The data represented the mean values of five repeats. The data are shown as the means \pm SD (Student T-test, *p < 0.05). **b** Flow cytometry analysis of the cell cycle after the transfection of miR-18a. **c** Cell cycle distribution of cells in S phase. The data were presented as the means \pm SD of four replicates (Student T-test, *p < 0.05; *p < 0.01)